Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has announced that the US FDA has accepted the review of a new prefilled syringe presentation for its shingles vaccine, Shingrix. This new format aims to simplify the administration process for healthcare professionals and is expected to be decided upon by June 20, 2025. This development represents a significant regulatory step for GSK’s Shingrix, which has been a vital component of shingles prevention since 2017, and highlights the company’s commitment to innovation in its product offerings.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company that focuses on uniting science, technology, and talent to advance health and disease prevention. The company is known for developing vaccines, like Shingrix, and other pharmaceuticals that address various health issues worldwide.
YTD Price Performance: 1.00%
Average Trading Volume: 8,234,814
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £55.5B
See more data about GSK stock on TipRanks’ Stock Analysis page.
